Form 4: TELA Bio Director Douglas Evans Receives Significant Equity Grant

TELA Bio, Inc. Director Douglas G. Evans was granted 7,950 restricted stock units and options to purchase 11,700 shares of common stock, aligning his interests with shareholders.

Summary

• Douglas G. Evans, a Director of TELA Bio, Inc. (TELA), acquired 7,950 shares of common stock in the form of restricted stock units (RSUs) on May 28, 2025, at a price of $0 per share.
• He also acquired options to purchase 11,700 shares of common stock on May 28, 2025, with an exercise price of $1.39 per share and an acquisition price of $0.
• Following these transactions, Mr. Evans beneficially owns 18,470 shares of common stock directly.
• Additionally, he directly owns 11,700 derivative securities in the form of stock options.
• Both the restricted stock units and stock options are subject to vesting, which occurs on the earlier of May 28, 2026, the next annual meeting of stockholders, or a Change in Control, contingent on his continued service.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the equity grant aligns the director's interests with shareholders, indicating continued commitment, which is a standard and generally favorable corporate governance practice.

Positives

• The grant of restricted stock units and stock options to Director Douglas G. Evans aligns his financial interests directly with the long-term performance and shareholder value of TELA Bio, Inc.
• Equity compensation is a standard practice for retaining and incentivizing key management and board members, signaling continued commitment from the director.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon the reporting person's continued service through the applicable vesting date, meaning the benefits are not guaranteed if service ceases prematurely.

Future Outlook

The granted restricted stock units and stock options are set to vest on the earlier of May 28, 2026, the next annual meeting of stockholders, or a Change in Control, provided the director continues his service.

Management Comments

• The transaction indicates the company's ongoing practice of using equity-based compensation to incentivize and retain its directors, aligning their interests with long-term shareholder value.

Industry Context

The grant of equity compensation to a director is a common practice across industries, particularly in publicly traded companies, to align the interests of board members with those of the shareholders and to incentivize long-term performance.

Corporate Governance

Related Party Transactions

• The acquisition of common stock and stock options by Director Douglas G. Evans from TELA Bio, Inc. constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to more focused efforts on long-term value creation.
• Employees: While not directly impacting employees, the compensation structure for leadership can influence overall company culture and performance expectations.

Next Steps

• The restricted stock units and stock options will vest according to the specified schedule, contingent on the director's continued service.

Key Dates

Keywords

TELA Bio, Form 4, insider transaction, equity grant, restricted stock units, stock options, director compensation, beneficial ownership, TELA